Published on 01/12/2025

Supplier/Partner Change Notifications: SLAs

Introduction to Serialization Change Control

In the pharmaceutical industry, maintaining compliance with regulations such as the Drug Supply Chain Security Act (DSCSA) in the US and the EU Falsified Medicines Directive (FMD) is imperative. Serialization is critical for tracking and tracing pharmaceutical products through the supply chain, ensuring drug safety and efficacy. This article provides a step-by-step guide to managing Supplier/Partner Change Notifications related to serialization and aggregation, with a focus on Service Level Agreements (SLAs). We will delve into master data flows, reconciliation rules, test processes, and exception handling, all while emphasizing the importance of data integrity, particularly under the ALCOA+ principles.

Understanding Serialization Requirements

Serialization involves assigning a unique identifier to each saleable unit and packaging of a prescription product. This identifier must be capable of being read and verified by both humans and automated systems. Understanding the key attributes of serialization requirements allows pharmaceutical companies to set up robust processes that are compliant with both US and EU regulations.

The first step in implementing serialization is defining user requirements specifications (URS) related to the product’s tracking system. This requirement encompasses the identification of data formats, security requirements, and data transfer protocols. A well-structured URS should address the following points:

• Data Format: Define the standard format for serialization numbers.
• Security Requirements: Specify encryption standards to protect sensitive data.
• Data Transfer Protocols: Outline the logistics of how data will be sent and stored.

After this initial groundwork, companies should establish their serialization and aggregation systems, ensuring that they can support real-time data sharing across the supply chain. The aggregation hierarchy must also be defined, detailing how different levels of packaging relate to one another, which is crucial for regulatory compliance.

Establishing Service Level Agreements (SLAs)

Service Level Agreements play a vital role in managing the expectations and responsibilities of all parties involved in the serialization process. An effective SLA defines the quality of service expectations that partners must meet when reporting changes associated with product serialization.

Key components of an SLA in the realm of serialization should include:

• Change Notification Timeliness: Suppliers must notify all relevant parties of changes in a predefined time frame, typically within 24 to 72 hours.
• Data Integrity Commitment: SLA should ensure that all data provided adheres to ALCOA+ principles—Attributable, Legible, Contemporaneous, Original, Accurate.
• Exception Handling Procedures: Clearly outline protocols in case of discrepancies during aggregation or serialization processes.

Additionally, companies should implement periodic audits of the SLA terms to ensure compliance and identify opportunities for process improvements. Such audits may include reviewing exception handling procedures, test results on serialization, and the effectiveness of reconciliation rules.

Implementing Testing Procedures for Serialization

Testing is an integral part of ensuring that serialization and aggregation systems function as intended. It includes verifying the systems against their URS to confirm compliance with both industry standards and internal policies. The testing should consist of the following phases:

1. Unit Testing

Unit testing verifies that individual components of the serialization system function correctly. This includes testing the barcode generation processes for accuracy and compliance with standards outlined in the URS. Unit tests should be automated where feasible, ensuring consistent results over time.

2. Integration Testing

Once unit testing is complete, integration testing validates the interaction between different system components. This is especially crucial for systems that integrate with external partners for serialization data transfer. During this phase, it is vital to test data flow, ensuring seamless communication between serialization systems and external databases.

3. User Acceptance Testing (UAT)

User Acceptance Testing is the penultimate step before the final rollout of a serialization system. Here, stakeholders must interact with the system to confirm that it meets their needs as specified in the URS. Critical tests during UAT should evaluate how well the system handles real-world scenarios, including potential changes and exception handling.

4. Validation of Results

After all testing phases, a summary report should be generated that documents the results. Discrepancies and any changes required must be integrated into the system, followed by re-testing, if necessary. This validation phase aligns with the regulatory expectations of maintaining a proper audit trail.

Data Integrity and Compliance with ALCOA+ Principles

Data integrity is a foundational principle within the pharmaceutical industry, especially concerning serialization and aggregation. The ALCOA+ principles serve as a guideline for maintaining this integrity throughout the system’s lifecycle:

• Attributable: All data must indicate who performed the action and when.
• Legible: Information should be clear and understandable, minimizing any potential ambiguity.
• Contemporaneous: Data should be recorded in real-time or close to the actual events to maintain accuracy.
• Original: The original records should be preserved following any potential changes.
• Accurate: Information must be verified and corrected where necessary, ensuring high accuracy levels.

Implementing controls to uphold ALCOA+ standards will prevent breaches of data integrity and ensure compliance with regulatory expectations set by authorities like the US FDA and EMA. Regular audits and review processes should be established to monitor these practices continually.

Exception Handling and Rework Procedures

Exception handling is crucial in serialization change control to maintain compliance and quality assurance. Situations where serialization data may require reworking include discrepancies in data entries, failed tests, and changes to packaging configurations. A structured approach to exception handling includes the following steps:

1. Identification of Exceptions

Clear procedures must be in place to identify and categorize any exceptions that arise during serialization processes. This includes routine checks and exception reports from system users.

2. Root Cause Analysis

For each identified exception, a root cause analysis should be conducted to understand why the error occurred. This may involve reviewing training records, SOP compliance, and system functionality.

3. Corrective and Preventive Actions (CAPA)

Based on the findings of the root cause analysis, necessary corrective and preventive actions should be instigated. This could include retraining staff, updating Standard Operating Procedures (SOPs), or modifying system configurations.

4. Documentation and Follow-up

All exception handling efforts should be meticulously documented. This documentation should include details of the issues, actions taken, and follow-up audits to ensure that the rework has been successfully, and that similar issues are less likely to reoccur in the future.

Conclusion: Ensuring Effective Change Control in Serialization

Serialization is an ongoing process that requires continual oversight and management. By developing robust SLAs, conducting rigorous testing, upholding data integrity under ALCOA+ principles, and having comprehensive exception handling procedures in place, pharmaceutical organizations can maintain compliance with regulatory expectations for serialization and aggregation.

In the context of evolving regulations and supply chain dynamics, it is essential to keep abreast of the latest regulatory guidance. By following the outlined steps and integrating best practices, organizations can secure their positions in the competitive pharmaceutical landscape while ensuring patient safety through effective serialization management and compliance.